✦ 24h Briefing Top Stories World U.S.India Business Technology Science Health Sports Entertainment

Loading

Fetching the latest headlines…

NabkaNews aggregates headlines from thousands of publishers worldwide via Google News, and provides AI-generated summaries and briefings for convenience. Every story links to its original source. We do not host or claim ownership of third-party reporting, and AI summaries may contain errors — always verify with the original source.

24h Briefing Top Stories World U.S.India Business Technology Science Health Sports Entertainment

Disclaimer Privacy Policy Terms of Use

© 2026 NabkaNews · World · U.S. · India — updated continuously. NabkaNews is an independent news aggregator and is not affiliated with any publisher shown.

Eli Lilly wins US approval for weight-loss pill · NabkaNews

← Back to headlines

Eli Lilly wins US approval for weight-loss pill

Financial Times·Apr 1

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Eli Lilly has received US approval for a weight-loss pill, specifically for obesity. The approval is expected to set up competition with rival Novo Nordisk in the market for GLP-1 pills. The development may also have implications for the companies' preparations for Medicare coverage.

Full coverage

Lilly's weight-loss pill wins US approval, sets up next battle with rival Novo Nordisk

Lilly’s weight-loss pill wins FDA approval

Eli Lilly wins FDA approval for weight loss pill, tees up Novo rivalry

Pharmaceutical Technology·Apr 2

FDA approves Lilly obesity pill, triggering battle with Novo Nordisk

BioPharma Dive·Apr 1

Lilly’s Obesity Pill Gets US Approval in Fresh Challenge to Novo

Bloomberg.com·Apr 1

Lilly’s Obesity Pill Approval Kicks Off New Front in Weight-Loss Drug Wars

Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage

Lilly's weight-loss pill wins US approval; sets up next battle with rival Novo Nordisk

The Detroit News·Apr 1

View original report at Financial Times ↗